Bluejay Diagnostics (Bluejay Diagnostics) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bluejay Diagnostics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bluejay Diagnostics's Operating Income for the three months ended in Mar. 2024 was $ -2.43 Mil. Bluejay Diagnostics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Bluejay Diagnostics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bluejay Diagnostics Interest Expense Historical Data

The historical data trend for Bluejay Diagnostics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Interest Expense Chart

Bluejay Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.03

-0.37

Bluejay Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial												-	-	-	-	-

Bluejay Diagnostics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Bluejay Diagnostics (NAS:BJDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bluejay Diagnostics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-2.43 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.17 Mil.

Bluejay Diagnostics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Bluejay Diagnostics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Bluejay Diagnostics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089